Related Experiment Video
Updated: Aug 19, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Development and implementation of an immunotherapy unit in a urology department
M Rodrigo-Aliaga1, M Bosquet-Sanz1, L Barrios-Arnau1
1Unidad de Uro-Oncología, Servicio de Urología, Hospital General Universitario de Castellón, Castellón, Spain.
Introduction:
Immunotherapy is revolutionizing cancer treatment, with monoclonal antibodies directed against checkpoint regulatory molecules currently being the most widely used therapy. A total of six immune checkpoint inhibitor (CPI) drugs have been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in various solid tumors of the genitourinary tract.
Material And Methods:
The literature is reviewed and the methodology, as well as our own experience, are analyzed to establish treatment with CPIs in a urology department.
Results:
The requirements recommended in terms of training, logistics and procedure are described in order to safely offer expert treatment with CPIs to patients with genitourinary tumors.
Conclusions:
Compliance with the proposed program ensures safe administration of immune checkpoint inhibitors in a hospital setting.
